These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

225 related items for PubMed ID: 23931023

  • 1. Targeted therapy and new anticancer drugs in advanced disease.
    Silva S, Danson S.
    Thorac Surg Clin; 2013 Aug; 23(3):411-9. PubMed ID: 23931023
    [Abstract] [Full Text] [Related]

  • 2. Directed therapies in lung cancer: new hope?
    Parente Lamelas I, Abal Arca J, Fírvida Pérez JL.
    Arch Bronconeumol; 2012 Oct; 48(10):367-71. PubMed ID: 22551924
    [Abstract] [Full Text] [Related]

  • 3. Lung Cancer Genomics in the Era of Accelerated Targeted Drug Development.
    Wijesinghe P, Bollig-Fischer A.
    Adv Exp Med Biol; 2016 Oct; 890():1-23. PubMed ID: 26703796
    [Abstract] [Full Text] [Related]

  • 4. Update on systemic therapy of advanced non-small-cell lung cancer.
    Cufer T, Knez L.
    Expert Rev Anticancer Ther; 2014 Oct; 14(10):1189-203. PubMed ID: 25098682
    [Abstract] [Full Text] [Related]

  • 5. [Is chemotherapy still an option in oncogene-addicted non-small cell lung cancer? No].
    Girard N.
    Bull Cancer; 2015 Jun; 102(6 Suppl 1):S96-9. PubMed ID: 26118885
    [Abstract] [Full Text] [Related]

  • 6. Targeted Therapies for Non-Small Cell Lung Cancer: An Update on Epidermal Growth Factor Receptor and Anaplastic Lymphoma Kinase Inhibitors.
    Kreamer K, Riordan D.
    Clin J Oncol Nurs; 2015 Dec; 19(6):734-42. PubMed ID: 26583637
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Adjuvant therapy for EGFR mutant and ALK positive NSCLC: Current data and future prospects.
    Chuang JC, Neal JW, Niu XM, Wakelee HA.
    Lung Cancer; 2015 Oct; 90(1):1-7. PubMed ID: 26275476
    [Abstract] [Full Text] [Related]

  • 11. Predictors of biomarkers guiding targeted therapeutic strategies in locally advanced lung cancer.
    Cottini F, Lautenschlaeger T.
    Cancer J; 2013 Oct; 19(3):263-71. PubMed ID: 23708073
    [Abstract] [Full Text] [Related]

  • 12. Targeting the MET gene for the treatment of non-small-cell lung cancer.
    Gelsomino F, Facchinetti F, Haspinger ER, Garassino MC, Trusolino L, De Braud F, Tiseo M.
    Crit Rev Oncol Hematol; 2014 Feb; 89(2):284-99. PubMed ID: 24355409
    [Abstract] [Full Text] [Related]

  • 13. Targeted therapies and non-small-cell lung cancer: new developments.
    Gridelli C.
    Curr Opin Oncol; 2007 Mar; 19(2):75-7. PubMed ID: 17272976
    [No Abstract] [Full Text] [Related]

  • 14. ALCHEMIST Trials: A Golden Opportunity to Transform Outcomes in Early-Stage Non-Small Cell Lung Cancer.
    Govindan R, Mandrekar SJ, Gerber DE, Oxnard GR, Dahlberg SE, Chaft J, Malik S, Mooney M, Abrams JS, Jänne PA, Gandara DR, Ramalingam SS, Vokes EE.
    Clin Cancer Res; 2015 Dec 15; 21(24):5439-44. PubMed ID: 26672084
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. The association between clinical prognostic factors and epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) efficacy in advanced non-small-cell lung cancer patients: a retrospective assessment of 94 cases with EGFR mutations.
    Lin JH, Lin D, Xu L, Wang Q, Hu HH, Xu HP, He ZY.
    Oncotarget; 2017 Jan 10; 8(2):3412-3421. PubMed ID: 27926500
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.